The quantitative response of human tumours to radiation and misonidazole.
Identifieur interne : 000512 ( Ncbi/Merge ); précédent : 000511; suivant : 000513The quantitative response of human tumours to radiation and misonidazole.
Auteurs : D. V. Ash ; M. J. Peckham ; G. G. SteelSource :
- British Journal of Cancer [ 0007-0920 ] ; 1979.
Abstract
Eleven patients with measurable subcutaneous or pulmonary metastases were selected for a study of the effectiveness of the radiosensitizer misonidazole (MIS). Evaluable data were obtained in 6 patients and radiosensitization demonstrated in 5. Patients were irradiated either before or after MIS, and each patient acted as his own control. Response to treatment in 5 cases was assessed in terms of growth delay, and radiation doses were selected in expectation of enhancement ratios of 1.2 to 1.5. In 1 case evidence of sensitization was obtained from differential tumour clearance from 2 areas of skin irradiated before or after MIS. Results in 4/5 growth-delay studies indicated enhancement ratios ranging from 1.1 to greater than 1.5. An enhancement ratio of 1.3 was measured in a case of squamous carcinoma treated by a 10-fraction course of irradiation. Evidence of sensitization was obtained in breast carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosarcoma. The results of this study support the view that MIS may improve the radiotherapeutic management of a wide range of tumours, although more extensive data are required to identify those categories of disease in which greatest benefit will be obtained, and to indicate the optimum radiation schedule.
Url:
PubMed: 526430
PubMed Central: 2010139
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000247
- to stream Pmc, to step Curation: 000246
- to stream Pmc, to step Checkpoint: 000446
Links to Exploration step
PMC:2010139Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The quantitative response of human tumours to radiation and misonidazole.</title>
<author><name sortKey="Ash, D V" sort="Ash, D V" uniqKey="Ash D" first="D. V." last="Ash">D. V. Ash</name>
</author>
<author><name sortKey="Peckham, M J" sort="Peckham, M J" uniqKey="Peckham M" first="M. J." last="Peckham">M. J. Peckham</name>
</author>
<author><name sortKey="Steel, G G" sort="Steel, G G" uniqKey="Steel G" first="G. G." last="Steel">G. G. Steel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">526430</idno>
<idno type="pmc">2010139</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010139</idno>
<idno type="RBID">PMC:2010139</idno>
<date when="1979">1979</date>
<idno type="wicri:Area/Pmc/Corpus">000247</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000247</idno>
<idno type="wicri:Area/Pmc/Curation">000246</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000246</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000446</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000446</idno>
<idno type="wicri:Area/Ncbi/Merge">000512</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The quantitative response of human tumours to radiation and misonidazole.</title>
<author><name sortKey="Ash, D V" sort="Ash, D V" uniqKey="Ash D" first="D. V." last="Ash">D. V. Ash</name>
</author>
<author><name sortKey="Peckham, M J" sort="Peckham, M J" uniqKey="Peckham M" first="M. J." last="Peckham">M. J. Peckham</name>
</author>
<author><name sortKey="Steel, G G" sort="Steel, G G" uniqKey="Steel G" first="G. G." last="Steel">G. G. Steel</name>
</author>
</analytic>
<series><title level="j">British Journal of Cancer</title>
<idno type="ISSN">0007-0920</idno>
<idno type="eISSN">1532-1827</idno>
<imprint><date when="1979">1979</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Eleven patients with measurable subcutaneous or pulmonary metastases were selected for a study of the effectiveness of the radiosensitizer misonidazole (MIS). Evaluable data were obtained in 6 patients and radiosensitization demonstrated in 5. Patients were irradiated either before or after MIS, and each patient acted as his own control. Response to treatment in 5 cases was assessed in terms of growth delay, and radiation doses were selected in expectation of enhancement ratios of 1.2 to 1.5. In 1 case evidence of sensitization was obtained from differential tumour clearance from 2 areas of skin irradiated before or after MIS. Results in 4/5 growth-delay studies indicated enhancement ratios ranging from 1.1 to greater than 1.5. An enhancement ratio of 1.3 was measured in a case of squamous carcinoma treated by a 10-fraction course of irradiation. Evidence of sensitization was obtained in breast carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosarcoma. The results of this study support the view that MIS may improve the radiotherapeutic management of a wide range of tumours, although more extensive data are required to identify those categories of disease in which greatest benefit will be obtained, and to indicate the optimum radiation schedule.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
<journal-title>British Journal of Cancer</journal-title>
<issn pub-type="ppub">0007-0920</issn>
<issn pub-type="epub">1532-1827</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">526430</article-id>
<article-id pub-id-type="pmc">2010139</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>The quantitative response of human tumours to radiation and misonidazole.</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Ash</surname>
<given-names>D. V.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Peckham</surname>
<given-names>M. J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Steel</surname>
<given-names>G. G.</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub"><month>12</month>
<year>1979</year>
</pub-date>
<volume>40</volume>
<issue>6</issue>
<fpage>883</fpage>
<lpage>889</lpage>
<abstract><p>Eleven patients with measurable subcutaneous or pulmonary metastases were selected for a study of the effectiveness of the radiosensitizer misonidazole (MIS). Evaluable data were obtained in 6 patients and radiosensitization demonstrated in 5. Patients were irradiated either before or after MIS, and each patient acted as his own control. Response to treatment in 5 cases was assessed in terms of growth delay, and radiation doses were selected in expectation of enhancement ratios of 1.2 to 1.5. In 1 case evidence of sensitization was obtained from differential tumour clearance from 2 areas of skin irradiated before or after MIS. Results in 4/5 growth-delay studies indicated enhancement ratios ranging from 1.1 to greater than 1.5. An enhancement ratio of 1.3 was measured in a case of squamous carcinoma treated by a 10-fraction course of irradiation. Evidence of sensitization was obtained in breast carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosarcoma. The results of this study support the view that MIS may improve the radiotherapeutic management of a wide range of tumours, although more extensive data are required to identify those categories of disease in which greatest benefit will be obtained, and to indicate the optimum radiation schedule.</p>
</abstract>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Ash, D V" sort="Ash, D V" uniqKey="Ash D" first="D. V." last="Ash">D. V. Ash</name>
<name sortKey="Peckham, M J" sort="Peckham, M J" uniqKey="Peckham M" first="M. J." last="Peckham">M. J. Peckham</name>
<name sortKey="Steel, G G" sort="Steel, G G" uniqKey="Steel G" first="G. G." last="Steel">G. G. Steel</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000512 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000512 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Terre |area= CobaltMaghrebV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:2010139 |texte= The quantitative response of human tumours to radiation and misonidazole. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:526430" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a CobaltMaghrebV1
This area was generated with Dilib version V0.6.32. |